ENDRA Life Sciences Inc. (NDRA)

Over the past six months, ENDRA Life Sciences, Inc. (NDRA) stock has experienced several notable events and fluctuations. The Board of Directors initiated a process to evaluate strategic alternatives to maximize shareholder value. The company reported its financial results, which included flagging a going-concern risk and a pivot to digital asset treasury, alongside sharp cuts in 2025 operating costs. The TAEUS® Liver Device demonstrated high-level consistency in a clinical study. Anthony DiGiandomenico, an Independent Director, purchased 70,822 shares. Shareholders have experienced substantial dilution in the past year, with total shares outstanding growing by 107.5%.

Information regarding the demand seasonality specifically for ENDRA Life Sciences, Inc.'s products and services is not explicitly available. Historically, buying NDRA stock in November has shown the highest probability of a positive return, whereas May has exhibited the lowest probability. This indicates stock market seasonality rather than a direct seasonality in the demand for the company's medical devices or services.

ENDRA Life Sciences, Inc. is a medical technology company focused on developing innovative ultrasound technologies. The company's primary product is the Thermo Acoustic Enhanced UltraSound (TAEUS®) system, which aims to visualize tissue with MRI-like quality at a lower cost. The initial focus is on measuring fat in the liver for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). ENDRA is also exploring other clinical uses for TAEUS®, including tissue composition analysis, temperature monitoring, and vascular imaging. Additionally, the Nexus 128 system is their first commercially available fully 3D photo-acoustic imaging system for lab researchers.

ENDRA Life Sciences, Inc. is headquartered in Ann Arbor, Michigan, United States. The TAEUS® technology is designed to integrate with over one million ultrasound systems globally and targets chronic liver conditions affecting a vast global population.

ENDRA Life Sciences' brand reputation has been influenced by both positive product development news and financial challenges. Positive developments include the TAEUS® Liver Device demonstrating high-level consistency in clinical studies. However, the company's financial situation has presented challenges, including the initiation of a review of strategic alternatives and flagging a going-concern risk. Analyst sentiment is mixed, with some analysts issuing "Strong Buy" ratings, while others assign a "Strong Sell" rating due to financial risks. MarketBeat reports a consensus rating of "Hold" for ENDRA Life Sciences.

ENDRA Life Sciences Inc. (NDRA) has a mix of institutional and individual owners. As of April 8, 2026, there were 7 institutional owners holding a total of 71,825 shares. Individual insiders collectively hold 6.08% of the shares, amounting to 70,912 shares. A notable individual transaction was the purchase of 70,822 shares by Independent Director Anthony DiGiandomenico in October 2025.